Last month, we discussed Aduhelm, Biogen’s recently-approved Alzheimer’s drug that received pushback from medical professionals who believe the FDA put the cart ahead of the horse. Now, according to a New York Times article, two major medical centers, Cleveland Clinic and Mount Sinai, have decided not to administer the drug to patients.
Major Medical Centers Are Nixing Aduhelm
The controversial new Alzheimer’s drug may be FDA-approved, but there’s no shortage of critics.
Jul 21, 2021
Recommended
Have You Heard About our Podcasts?
Through the Line podcasts explore innovations and information across the packaging and processing landscape. Join us for the latest insights, trends, and strategies shaping packaging and processing today.
Listen Today
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
Downloads
